Genital Neoplasms clinical trials at University of California Health

6 in progress, 3 open to eligible people

Showing trials for

  • Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

    open to eligible males ages 18 years and up

    The study will be conducted in 4 parts and will commence with dose escalation of VIR-5500 as a monotherapy (Part 1), followed by combination escalation (Part 3a), monotherapy dose expansion (Part 2) and combination dose expansion (Part 4a). - Part 1 (Monotherapy Dose Escalation): Single-agent VIR-5500 dose escalation - Part 2 (Monotherapy Dose Expansion): Single-agent VIR-5500 dose expansion - Part 3 (Combination Dose Escalation): VIR-5500 plus another therapeutic agent dose escalation Part 3a (Combination Dose Escalation): VIR-5500 in combination with an androgen receptor signaling inhibitor (ARSI) - Part 4 (Combination Dose Expansion): VIR-5500 plus another therapeutic agent dose expansion Part 4a (Combination Dose Expansion): VIR-5500 in combination with an androgen receptor signaling inhibitor (ARSI)

    at UCSF

  • Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

    open to eligible females ages 18 years and up

    This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

    at UCSF

  • PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery

    open to eligible females ages 18 years and up

    This study seeks to understand how frailty, a term that describes people who are more vulnerable stressors such as a new medical problem, affects the outcomes and quality of life in adult patients with gynecologic cancer.

    at UCSF

  • AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

    Sorry, in progress, not accepting new patients

    This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product. Backfill cohorts will enroll additional subjects at doses deemed to be safe for a total enrollment of up to 12 subjects per each backfill cohort on the protocol.

    at UCSF

  • ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

    Sorry, in progress, not accepting new patients

    This first-in-human, Phase 1/2, open-label study evaluates the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of JSB462 (luxdegalutamide, previously ARV-766) administered as monotherapy and in combination with abiraterone in participants with metastatic prostate cancer. The study includes dose-escalation and cohort expansion components to determine the recommended Phase 2 dose and assess clinical activity.

    at UCSD

  • Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

    “Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”

    Sorry, not currently recruiting here

    This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with advanced solid tumors that are antigen-rich.

    at UC Davis

Our lead scientists for Genital Neoplasms research studies include .

Last updated: